Cargando…
Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous Melanoma
SIMPLE SUMMARY: Although immunotherapy and targeted therapy have dramatically improved melanoma survival, some patients rapidly progress and decease within a few months after a stage IV diagnosis. Up until now, pathological, clinical and biological markers are known prognostic factors for survival o...
Autores principales: | Fröhlich, Fabienne, Ramelyte, Egle, Turko, Patrick, Dzung, Andreas, Freiberger, Sandra N., Mangana, Joanna, Levesque, Mitchell P., Dummer, Reinhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418148/ https://www.ncbi.nlm.nih.gov/pubmed/37568633 http://dx.doi.org/10.3390/cancers15153818 |
Ejemplares similares
-
Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational Burden
por: Ak, Melike, et al.
Publicado: (2021) -
The Prognostic Value of a Single, Randomly Timed Circulating Tumor DNA Measurement in Patients with Metastatic Melanoma
por: Boerlin, Aurelio, et al.
Publicado: (2022) -
Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma
por: Lang, Claudia C. V., et al.
Publicado: (2020) -
The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
por: Dummer, Reinhard, et al.
Publicado: (2023) -
What Is New in Cutaneous T Cell Lymphoma?
por: Morgenroth, Sarah, et al.
Publicado: (2023)